⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 1, 2024Open Access

Supplementary Figure S5 from FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma

Thomas M. Anderson Bryan H. Chang Alexander C. Huang Xiaowei Xu Daniel Yoon Catherine G. Shang Rosemarie Mick Erin Schubert Suzanne McGettigan Kristin Kreider Wei Xu E. John Wherry Lynn M. Schuchter Ravi K. Amaravadi Tara C. Mitchell Michael D. Farwell

View Full Paper

Ask AI

Bookmark

Share

Abstract

Supplementary Figure S5. Change in SUVmax in patients with <10 days between PET0 and therapy start.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Anderson et al. (2024) studied this question.

synapsesocial.com/papers/68e6c4b3b6db6435876435c8 https://doi.org/10.1158/1078-0432.25728803.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S5 from FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma2024
2Supplementary Figure S2 from FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma2024
3Supplementary Figure S2 from FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma2024
4Supplementary Figure S4 from FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma2024
5Supplementary Figure S1 from FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma2024